VRCA · Verrica Pharmaceuticals Inc.
$4.97
+0.11 (+2.26%)
At close · Aug 14
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists regarding its ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 6, 2026
Market Cap
$87.44M
Shares
17.18M
Verrica Pharmaceuticals Inc. Earnings Call Transcripts
Every quarterly earnings call for Verrica Pharmaceuticals Inc. (VRCA) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼64.9%
$2.92M
−$24.80M
'23 Q3
23-11-09
▲2823.5%
$1.99M
−$24.61M
'23 Q4
24-02-29
▲10240.5%
$3.83M
−$20.33M
'24 Q1
24-05-13
▲2744.5%
$5.18M
−$17.19M
'24 Q2
24-08-14
▼82.7%
$344,000
−$16.20M
'24 Q4
25-03-11
▼10.1%
$3.44M
−$9.74M
'25 Q1
25-05-13
▲145.4%
$12.70M
$204,000
'25 Q2
25-08-12
·
$14.34M
−$274,000
'25 Q3
25-11-14
▲1380.2%
$5.09M
−$8.07M
'25 Q4
26-03-11
▲46.1%
$5.02M
−$9.68M
'26 Q1
26-05-12
LATEST
▼53.8%
$5.86M
−$13.15M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Verrica Pharmaceuticals Inc. Q2 FY2026 Earnings Call
Confident tone
Common warts (COVID) Phase 3 program
International partnerships and launches
Pipeline asset VP315 in basal cell carcinoma
Revenue
$5.86M
▼ 53.8% YoY Diluted EPS
$-0.62
▼ 3200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Verrica Pharmaceuticals Inc. Q1 FY2026 Earnings Call
Confident tone
VP315 basal cell carcinoma program
Ycanth commercial momentum
Common warts Phase III (COV-2 / COV-3)
Revenue
$5.02M
▲ 46.1% YoY Diluted EPS
$-0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-11
Verrica Pharmaceuticals Inc. Q4 FY2025 Earnings Call
Revenue
$5.09M*
▲ 1380.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-14
Verrica Pharmaceuticals Inc. Q3 FY2025 Earnings Call
Positive tone
VP-315 basal cell carcinoma Phase III
YCANTH commercial growth and dispensed units
Global Phase III common warts with Torii
Revenue
$14.34M
Diluted EPS
$-0.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Verrica Pharmaceuticals Inc. Q2 FY2025 Earnings Call
Confident tone
YCANTH commercial growth
Pipeline expansion
Torii partnership and amended agreement
Revenue
$12.70M
▲ 145.4% YoY Diluted EPS
$0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Verrica Pharmaceuticals Inc. Q1 FY2025 Earnings Call
Revenue
$3.44M
▼ 10.1% YoY Diluted EPS
$-1.03
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Verrica Pharmaceuticals Inc. Q4 FY2024 Earnings Call
Positive tone
Pipeline Expansion - Common Warts and YCANTH Label Expansion
BP-315 / Basal Cell Carcinoma Program
Financial Position and Capital Raise
Revenue
$344,000*
▼ 82.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q2
2024-08-14
Verrica Pharmaceuticals Inc. Q2 FY2024 Earnings Call
Confident tone
YCANTH commercial launch and revenue
VP-315 basal cell carcinoma Phase 2 results
Distribution and GPO partnerships
Revenue
$5.18M
▲ 2744.5% YoY Diluted EPS
$-3.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Verrica Pharmaceuticals Inc. Q1 FY2024 Earnings Call
Confident tone
YCANTH commercial launch and revenue growth
Regulatory milestones and exclusivity
Pipeline advancement (common warts and VP-315)
Revenue
$3.83M
▲ 10240.5% YoY Diluted EPS
$-4.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-29
Verrica Pharmaceuticals Inc. Q4 FY2023 Earnings Call
Confident tone
YCANTH Commercial Launch
Reimbursement and Coverage
Distribution Expansion
Revenue
$1.99M*
▲ 2823.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Verrica Pharmaceuticals Inc. Q3 FY2023 Earnings Call
Revenue
$2.92M
▼ 64.9% YoY Diluted EPS
$-5.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-14
Verrica Pharmaceuticals Inc. Q2 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–12 of 12 earnings calls
Key facts
CIK
1660334
CUSIP
92511W207
13F (30d)
42 filings
42 filers
Visit website
Investor relations